Muscarinic Acetylcholine Receptor Market - Forecast(2023 - 2028)

Report Code: HCR 15142 Report Format: PDF + Excel

Muscarinic Acetylcholine Receptor Market Overview

Muscarinic Acetylcholine Receptor market size is forecast to reach $1.89 billion by 2026, growing at a CAGR of 4.1% during the forecast period 2021-2026. Muscarinic Acetylcholine Receptor are kind of receptors that are involved in regulating the number of peripheral and central functions and are able to inhibit postsynaptic neurons. They are responsible for mediating the effects basically the physiological effects of the nerve activity that are parasympathetic. It has both inhibitory as well as excitatory effects that can block or stimulate the response and is stored in the acetylcholine producing neurons as cholinergic neurons. It is an ester of acetic acid and choline that functions to transmit nerve impulses within the peripheral and central nervous systems. Increasing prevalence of disease such as chronic obstructive pulmonary disease and increasing importance of muscarinic acetylcholine disease therapeutics are the major factors driving the growth of the market. Growth in research in muscarinic acetylcholine and rise in the adoption of muscarinic acetylcholine receptor is set to further enhance the overall market development of the Muscarinic Acetylcholine Receptor Market for the period 2021-2026.

Muscarinic Acetylcholine Receptor Market  Report Coverage

The report: Muscarinic Acetylcholine Receptor Market Forecast (2021-2026), by Industry ARC, covers an in-depth analysis of the following segments of the Muscarinic Acetylcholine Receptor Market.

By Product: Tropicamide, Anauex-273, Nu-0467154, and Others.
By Test : M1, M4, M5, and Others.
By Application: Chronic Obstructive Pulmonary Disease, Attention Deficit Hyperactivity Disorder, Alzheimers Disease, Memory Impairment, and Psychiatric Disorders.
By Geography: North America (U.S., Canada, Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia, and New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina, and Rest of South America), and Rest of the World (Middle East, and Africa).

Key Takeaways         

  • North America dominated the Muscarinic Acetylcholine Receptor Market in 2020 owing to the increasing number of key players who are continuously focusing on developing M1 mAchR agonists for treating Alzheimer’s disease and increasing number of pharmaceutical companies that are working on new therapies for rare neurological conditions. The Muscarinic Acetylcholine Receptor Market scope for different regions will be provided in the final report.
  • Growing public awareness and technological advancements along with rising awareness about muscarinic acetylcholine & its prevention are likely to aid the market growth of the Muscarinic Acetylcholine Receptor Market report.
  • Detailed analysis of the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Muscarinic Acetylcholine Receptor Market report.
  • Inadequate funding and high cost involved in the treatment of the diseases is poised to create the hurdles for the Muscarinic Acetylcholine Receptor Market.

Muscarinic Acetylcholine Receptor Market Revenue Share, By Geography, 2020(%)

For More Details on This Report - Request for Sample

Muscarinic Acetylcholine Receptor Market Segment Analysis – By Product

Tropicamide held the largest share in the Muscarinic Acetylcholine Receptor Market in 2020 and is estimated to grow at a CAGR of 4.4% during the forecast period 2021-2026. Tropicamide is a muscarinic antagonist having similar actions to atropine with an anticholinergic property. It binds the muscarinic receptors in the ciliary muscle in the eye and in the sphincter. It inhibits the responses from stimulation and produces the dilation of the pupil along with the paralysis of the ciliary muscle. Tropicamide is a diagnostic agent that is used to produce short duration cycloplegia and mydriasis. Owing to the short duration of the effect, it is used during dilated fundus examination. Cycloplegic drops are used to treat uveitis that decreases the risk of synechiae and decreases the inflammation in the anterior chamber of the eye. Tropicamide are estimated to register the higher CAGR over the period 2021-2026.

Muscarinic Acetylcholine Receptor Market Segment Analysis – By Application

Chronic Obstructive Pulmonary Disease held the largest share in the Muscarinic Acetylcholine Receptor Market in 2020 and is estimated to grow at a CAGR of 4.3% during the forecast period 2021-2026. Muscarinic acetylcholine receptor controls smooth muscle tone, inflammation, and mucus secretion in healthy lungs. Cholinergic mechanisms contribute to increase mucus secretion and bronochoconstriction in chronic obstructive pulmonary disease. Muscarinic acetylcholine is not a neurotransmitter but it transcends the parasympathetic nervous system that can modify the phenotypic function of airway cells including the epithelial cells. Chronic Obstructive Pulmonary Disease are estimated to register the higher CAGR over the period 2021-2026.

Muscarinic Acetylcholine Receptor Market Segment Analysis – By Geography

North America dominated the Muscarinic Acetylcholine Receptor Market with a major share of 41.8% in 2020. This is attributed to the  increasing number of key players that are focusing on developing mAChR for the treatment of Alzeheimers’s disease and increasing number of pharmaceutical companies that are working on new therapies for neurological conditions. Increasing incidences of chronic obstructive pulmonary disease and increased research activity for therapeutic contribution of these receptors are also increasing the growth of the market in this region.

However, Asia Pacific is estimated to grow at a higher CAGR during the forecast period 2021-2026 owing to the increase in healthcare expenditure and rise in the demand for new treatment for Alzeheimer’s disease.

Muscarinic Acetylcholine Receptor Market Drivers

Increasing Prevalence of Chronic Obstructive Pulmonary Disease

Increasing prevalence of chronic obstructive pulmonary disease is increasing the growth of the Muscarinic Acetylcholine Receptor Market. Chronic obstructive pulmonary disease causes obstructed airflow from the lungs which includes difficulty in breathing, mucus, and cough. It is mainly caused by long term exposure to particulate matter and irritating gases. People suffering from this have high risk of developing heart disease, and variety of other conditions. Two most common conditions that contribute to it are Emphysema and chronic bronchitis which usually occurs together. It affects 2 to 8% of the population. Thus, increasing the growth of the Muscarinic Acetylcholine Receptor Market during the forecast period 2021-2026.

Rising Awareness About Muscarinic Acetylcholine Receptor

Rising awareness about muscarinic acetylcholine receptor is increasing the growth of the Muscarinic Acetylcholine Receptor Market. Neurotransmitter acetylcholine recognized by muscarinic receptors that translates into electrical transients and altered cell behavior by suppressing the signaling pathways. Awareness is rising among the people that it decreases the heart rate and helps in bronchial construction. It makes to breath in asthmatics and enhances the urination by relaxing and contracting the bladder.Thus, increasing the growth of the Muscarinic Acetylcholine Receptor Market during the forecast period 2021-2026.

Muscarinic Acetylcholine Receptor Market Challenges

Inadequate funding and high cost involved in the treatment of the diseases

Some of the factors that are set to impede the growth of the Muscarinic Acetylcholine Receptor Market are inadequate funding and high cost involved in the treatment of the disease. Strict approval process is also set to hinder the growth of the market.

Muscarinic Acetylcholine Receptor Market Landscape

Product launches, mergers and acquisitions, joint ventures, and R&D activities are key strategies adopted by players in the Muscarinic Acetylcholine Receptor Market. In 2020, the Muscarinic Acetylcholine Receptor Market share is consolidated by the top ten players present in the market. The Muscarinic Acetylcholine Receptor Market, top 10 companies are Heptares Therapeutics Ltd., Astrazeneca Plc, Karuna Pharmaceuticals Inc., Anavex Life Sciences Corp., NeuroHealing Pharmaceuticals Inc. and Sumitomo Dainippon Pharma Co. Ltd. among others.

Relevant Titles:

Proteinuria Treatment Market - Forecast(2021 - 2026)

Report Code: HCR 0358

Hydroxytryptamine Receptor Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth And Forecast 2019 - 2024

Report Code: HCR 67552

For more Lifesciences and Healthcare Market reports, please click here

1. Muscarinic Acetylcholine Receptor Market- Overview
    1.1 Definitions and Scope
2. Muscarinic Acetylcholine Receptor Market- Executive Summary
    2.1 Market Revenue and Key Trends by Company
    2.2 Key trends by Product
    2.3 Key trends by Type
    2.4 Key trends by Application
    2.5 Key trends by Geography
3. Muscarinic Acetylcholine Receptor Market– Comparative Analysis
    3.1 Product Benchmarking – Key Companies
    3.2 Financial Analysis – Key Companies
    3.3 Market Value Split by Key Companies
    3.4 Patent Analysis – Key Companies
    3.5 Pricing Analysis
4. Muscarinic Acetylcholine Receptor Market- Startup Companies Scenario Premium
    4.1 Key Startup Company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Muscarinic Acetylcholine Receptor Market– Industry Market Entry Scenario Premium Premium
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Muscarinic Acetylcholine Receptor Market Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. Muscarinic Acetylcholine Receptor Market– Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Muscarinic Acetylcholine Receptor Market– By Product(Market Size –$Million/$Billion)
    8.1 Tropicamide
    8.2 Anauex-273
    8.3 Nu-0467154
    8.4 Others
9. Muscarinic Acetylcholine Receptor Market– By Type(Market Size –$Million/$Billion)
    9.1 M1
    9.2 M4
    9.3 M5
    9.4 Others
10. Muscarinic Acetylcholine Receptor Market– By Application (Market Size –$Million/$Billion)
    10.1 Chronic Obstructive Pulmonary Disease
    10.2 Attention Deficit Hyperactivity Disorder
    10.3 Alzeheimers Disease
    10.4 Memory Impairment
    10.5 Psychiatric Disorders
11. Muscarinic Acetylcholine Receptor Market- By Geography(Market Size –$Million/$Billion)
    11.1 North America
        11.1.1 U.S.
        11.1.2 Mexico
        11.1.3 Canada
    11.2 Europe
        11.2.1 U.K.
        11.2.2 France
        11.2.3 Germany
        11.2.4 Italy
        11.2.5 Spain
        11.2.6 Russia
        11.2.7 Rest of Europe
    11.3 Asia Pacific
        11.3.1 China
        11.3.2 India
        11.3.3 Japan
        11.3.4 South Korea
        11.3.5 Australia & New Zealand
        11.3.6 Rest of Asia Pacific
    11.4  South America
        11.4.1 Brazil
        11.4.2 Argentina
        11.4.3 Rest of South America
    11.5 Rest of the World
        11.5.1 Middle East
        11.5.2 Africa
12. Muscarinic Acetylcholine Receptor Market- Entropy
13. Muscarinic Acetylcholine Receptor Market– Industry/Segment Competition Landscape Premium
    13.1 Market Share Analysis
        13.1.1 Global Market Share – Key Companies
        13.1.2 Market Share by Region – Key companies
        13.1.3 Market Share by Countries – Key Companies
        13.1.4 Best Practices for Companies
14. Muscarinic Acetylcholine Receptor Market– Key Company List by Country Premium Premium
15. Muscarinic Acetylcholine Receptor Market Company Analysis
    15.1 Company 1
    15.2 Company 2
    15.3 Company 3
    15.4 Company 4
    15.5 Company 5
    15.6 Company 6
    15.7 Company 7
    15.8 Company 8
    15.9 Company 9
    15.10 Company 10
"*Financials for private companies would be provided on a best efforts basis”.

LIST OF TABLES

1.Global MUSCARINIC ACETYLCHOLINE RECEPTOR MARKET, BY TYPE Market 2019-2024 ($M)
1.1 M1 Market 2019-2024 ($M) - Global Industry Research
1.2 M4 Market 2019-2024 ($M) - Global Industry Research
1.3 M5 Market 2019-2024 ($M) - Global Industry Research
2.Global MUSCARINIC ACETYLCHOLINE RECEPTOR MARKET, BY TYPE Market 2019-2024 (Volume/Units)
2.1 M1 Market 2019-2024 (Volume/Units) - Global Industry Research
2.2 M4 Market 2019-2024 (Volume/Units) - Global Industry Research
2.3 M5 Market 2019-2024 (Volume/Units) - Global Industry Research
3.North America MUSCARINIC ACETYLCHOLINE RECEPTOR MARKET, BY TYPE Market 2019-2024 ($M)
3.1 M1 Market 2019-2024 ($M) - Regional Industry Research
3.2 M4 Market 2019-2024 ($M) - Regional Industry Research
3.3 M5 Market 2019-2024 ($M) - Regional Industry Research
4.South America MUSCARINIC ACETYLCHOLINE RECEPTOR MARKET, BY TYPE Market 2019-2024 ($M)
4.1 M1 Market 2019-2024 ($M) - Regional Industry Research
4.2 M4 Market 2019-2024 ($M) - Regional Industry Research
4.3 M5 Market 2019-2024 ($M) - Regional Industry Research
5.Europe MUSCARINIC ACETYLCHOLINE RECEPTOR MARKET, BY TYPE Market 2019-2024 ($M)
5.1 M1 Market 2019-2024 ($M) - Regional Industry Research
5.2 M4 Market 2019-2024 ($M) - Regional Industry Research
5.3 M5 Market 2019-2024 ($M) - Regional Industry Research
6.APAC MUSCARINIC ACETYLCHOLINE RECEPTOR MARKET, BY TYPE Market 2019-2024 ($M)
6.1 M1 Market 2019-2024 ($M) - Regional Industry Research
6.2 M4 Market 2019-2024 ($M) - Regional Industry Research
6.3 M5 Market 2019-2024 ($M) - Regional Industry Research
7.MENA MUSCARINIC ACETYLCHOLINE RECEPTOR MARKET, BY TYPE Market 2019-2024 ($M)
7.1 M1 Market 2019-2024 ($M) - Regional Industry Research
7.2 M4 Market 2019-2024 ($M) - Regional Industry Research
7.3 M5 Market 2019-2024 ($M) - Regional Industry Research

LIST OF FIGURES

1.US Muscarinic Acetylcholine Receptor Market Revenue, 2019-2024 ($M)
2.Canada Muscarinic Acetylcholine Receptor Market Revenue, 2019-2024 ($M)
3.Mexico Muscarinic Acetylcholine Receptor Market Revenue, 2019-2024 ($M)
4.Brazil Muscarinic Acetylcholine Receptor Market Revenue, 2019-2024 ($M)
5.Argentina Muscarinic Acetylcholine Receptor Market Revenue, 2019-2024 ($M)
6.Peru Muscarinic Acetylcholine Receptor Market Revenue, 2019-2024 ($M)
7.Colombia Muscarinic Acetylcholine Receptor Market Revenue, 2019-2024 ($M)
8.Chile Muscarinic Acetylcholine Receptor Market Revenue, 2019-2024 ($M)
9.Rest of South America Muscarinic Acetylcholine Receptor Market Revenue, 2019-2024 ($M)
10.UK Muscarinic Acetylcholine Receptor Market Revenue, 2019-2024 ($M)
11.Germany Muscarinic Acetylcholine Receptor Market Revenue, 2019-2024 ($M)
12.France Muscarinic Acetylcholine Receptor Market Revenue, 2019-2024 ($M)
13.Italy Muscarinic Acetylcholine Receptor Market Revenue, 2019-2024 ($M)
14.Spain Muscarinic Acetylcholine Receptor Market Revenue, 2019-2024 ($M)
15.Rest of Europe Muscarinic Acetylcholine Receptor Market Revenue, 2019-2024 ($M)
16.China Muscarinic Acetylcholine Receptor Market Revenue, 2019-2024 ($M)
17.India Muscarinic Acetylcholine Receptor Market Revenue, 2019-2024 ($M)
18.Japan Muscarinic Acetylcholine Receptor Market Revenue, 2019-2024 ($M)
19.South Korea Muscarinic Acetylcholine Receptor Market Revenue, 2019-2024 ($M)
20.South Africa Muscarinic Acetylcholine Receptor Market Revenue, 2019-2024 ($M)
21.North America Muscarinic Acetylcholine Receptor By Application
22.South America Muscarinic Acetylcholine Receptor By Application
23.Europe Muscarinic Acetylcholine Receptor By Application
24.APAC Muscarinic Acetylcholine Receptor By Application
25.MENA Muscarinic Acetylcholine Receptor By Application
26.HEPTARES THERAPEUTICS LTD., Sales /Revenue, 2015-2018 ($Mn/$Bn)
27.SUMITOMO DAINIPPON PHARMA CO. LTD., Sales /Revenue, 2015-2018 ($Mn/$Bn)
28.ANAVEX LIFE SCIENCES CORP., Sales /Revenue, 2015-2018 ($Mn/$Bn)
29.NEUROHEALING PHARMACEUTICALS INC., Sales /Revenue, 2015-2018 ($Mn/$Bn)
30.ASTRAZENECA PLC., Sales /Revenue, 2015-2018 ($Mn/$Bn)
31.KARUNA PHARMACEUTICALS INC., Sales /Revenue, 2015-2018 ($Mn/$Bn)